Strengthening Pharmacovigilance Reporting for Withdrawal Reactions to Support Deprescribing
Clinical Pharmacology & Therapeutics · 2026-09 · 120 (3) · 663-666
DOI: 10.1002/cpt.70356 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 06.06.2026. Verfasst von Zakir Khan und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Hauptthemen laut MEDLINE: Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Deprescriptions, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pharmacovigilance plays a crucial role in post‐marketing surveillance of medicines and relies on the spontaneous reporting of adverse drug reactions (ADRs). Discontinuation of a drug can cause clinically relevant signs and symptoms, including withdrawal reactions; however, this subset of ADRs is not fully accommodated in current pharmacovigilance practice. We discuss proposed revisions to current ADR forms that could enhance the capture of withdrawal reaction evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
ORCID-Profile: Zakir Khan, Frank Moriarty
Zitieren
APA
Khan, Z., & Moriarty, F. (2026). Strengthening Pharmacovigilance Reporting for Withdrawal Reactions to Support Deprescribing. Clinical Pharmacology & Therapeutics, 120(3), 663-666. https://doi.org/10.1002/cpt.70356
Vancouver
Khan Z, Moriarty F. Strengthening Pharmacovigilance Reporting for Withdrawal Reactions to Support Deprescribing. Clinical Pharmacology & Therapeutics. 2026;120(3):663-666. doi:10.1002/cpt.70356
BibTeX
@article{Khan2026,
author = {Khan, Zakir and Moriarty, Frank},
title = {Strengthening Pharmacovigilance Reporting for Withdrawal Reactions to Support Deprescribing},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {120},
number = {3},
pages = {663--666},
doi = {10.1002/cpt.70356}
}
EUVIMED